CD103 + CD8 + tissue‐resident memory T lymphocytes of melanoma boost anti‐tumour immunity and predict immunotherapy outcomes
Clinical and Translational Medicine · 2025
DOI: 10.1002/ctm2.70464 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Translational Medicine, 2025. Verfasst von Tianyi Zhang und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Plastic Surgery, Zhongshan Hospital, Fudan University, Shanghai, PR China. Hauptthemen laut MEDLINE: CD8-Positive T-Lymphocytes, Melanoma, Integrin alpha Chains, Immunotherapy. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, China Postdoctoral Science Foundation, Shanghai Municipal Health Commission Collaborative Innovation Cluster Project.
Abstract (Originalsprache)
Background
Immunotherapy has revolutionised melanoma treatment, providing significant clinical benefits by reactivating the anti‐tumour immune system. CD8 + tissue‐resident memory T lymphocytes (CD8 + TRM) have emerged as crucial mediators of anti‐tumour immunity, while their specific role in melanoma remains poorly understood.
Methods
Following CD8 + CD45.1 + OT‐1 cell adoptive transfer into CD45.2 + mice, we employed magnetic separation to purify and analyse resident memory CD8 + T cells (TRM). We use multiple immunohistochemistry (mIHC) to evaluate the spatial distribution of CD8 + TRM in ZS melanoma cohort. Additionally, the biological function of CD8 + TRM and their impact on anti‐tumour immunity are explored using scRNA sequencing and spatial transcriptomics, coupled with in vivo/in vitro experiments. Finally, CD8 + TRM utility as an immunotherapy response predictor is examined across several independent cohorts.
Results
CD8 + TRM demonstrates potent tumour‐killing capabilities in melanoma, with CD103 as a distinctive marker. High CD103 + CD8 + TRM infiltration in tumour tissues strongly correlates with improved prognosis in melanoma patients. In vivo adoptive transfer of CD103 + CD8 + TRM effectively inhibits melanoma progression. Mechanistically, CD103 activates the integrin‐dependent PI3K/AKT signalling cascade, promoting both proliferation and anti‐tumour effector functions of CD8 + TRM. Notably, CD103 + CD8 + TRM preferentially localises within tertiary lymphoid structures (TLS), and its adoptive transfer promotes TLS formation. Clinically, CD103 + CD8 + TRM is enriched in immunotherapy‐responsive patients and serves as a strong predictor for immune checkpoint blockade (ICB) treatment outcomes.
Conclusions
CD103 + CD8 + TRM cells in melanoma play a key role in the anti‐tumour immune process and can also be used as a reliable predictor of immunotherapy efficacy. Key points CD103 is a reliable marker of tissue‐resident memory (TRM) CD8 + T cells in melanoma. CD103 + CD8 + TRM cells exhibit potent anti‐tumour immune activity. CD103 + CD8 + TRM cells predict favourable responses to immunotherapy in melanoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Plastic Surgery, Zhongshan Hospital, Fudan University, Shanghai, PR China.
- Clinical Center for Biotherapy, Zhongshan Hospital, Fudan University, Shanghai, PR China.
- Department of Plastic and Reconstructive Surgery, Zhongshan Hospital (Xiamen), Fudan University, Shanghai, PR China.
- Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai, PR China.
- Department of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, PR China.
ORCID-Profile: Tianyi Zhang, Jianying Gu
Förderung
- National Natural Science Foundation of China
- China Postdoctoral Science Foundation
- Shanghai Municipal Health Commission Collaborative Innovation Cluster Project
- Shanghai Sailing Program
Zitieren
APA
Zhang, T., Song, J., Li, Y., Shen, K., Xuan, J., Gao, Y., Lu, L., Pang, Z., Wang, L., Yang, Y., Gao, Z., Hu, Q., Zhu, Y., Wei, C., Zheng, S., Luo, R., Hou, Y., Zhou, Y., Wei, C., & Gu, J. (2025). CD103 + CD8 + tissue‐resident memory T lymphocytes of melanoma boost anti‐tumour immunity and predict immunotherapy outcomes. Clinical and Translational Medicine. https://doi.org/10.1002/ctm2.70464
Vancouver
Zhang T, Song J, Li Y, Shen K, Xuan J, Gao Y, et al. CD103 + CD8 + tissue‐resident memory T lymphocytes of melanoma boost anti‐tumour immunity and predict immunotherapy outcomes. Clinical and Translational Medicine. 2025. doi:10.1002/ctm2.70464
BibTeX
@article{Zhang2025,
author = {Zhang, Tianyi and Song, Junquan and Li, Yinlam and Shen, Kangjie and Xuan, Jiangying and Gao, Yuan and Lu, Lili and Pang, Zhi and Wang, Lu and Yang, Yang and Gao, Zixu and Hu, Qianrong and Zhu, Yu and Wei, Chenlu and Zheng, Shaoluan and Luo, Rongkui and Hou, Yingyong and Zhou, Yuhong and Wei, Chuanyuan and Gu, Jianying},
title = {CD103 + CD8 + tissue‐resident memory T lymphocytes of melanoma boost anti‐tumour immunity and predict immunotherapy outcomes},
journal = {Clinical and Translational Medicine},
year = {2025},
doi = {10.1002/ctm2.70464}
}
EUVIMED